Boey M L, Loizou S, Colaco C B, Matkin J A, Hughes G R
Clin Exp Rheumatol. 1984 Jan-Mar;2(1):53-6.
Plasma antithrombin III (AT III) was studied in 39 patients with systemic lupus erythematosus (SLE) and in 12 patients with other connective tissue disorders. AT III was measured immunologically by the Mancini method as well as by functional assay using thrombin and the chromogenic substrate, chromozyn TH (Boehringer). Reduced AT III activity was found in 17 patients; 8 had thrombosis. In 6 patients low AT III correlated with disease exacerbations and 2 had systemic vasculitis. No significant correlation could be demonstrated between low AT III levels and thromboembolic disease. A marked variation of functional AT III activity was observed in 30 patients in whom the presence of the lupus anticoagulant was demonstrated. The significance of this association is discussed.
对39例系统性红斑狼疮(SLE)患者和12例其他结缔组织病患者的血浆抗凝血酶III(AT III)进行了研究。采用曼奇尼法通过免疫测定法以及使用凝血酶和发色底物chromozyn TH(勃林格公司)的功能测定法来检测AT III。在17例患者中发现AT III活性降低;8例发生了血栓形成。在6例患者中,低AT III水平与疾病加重相关,2例患有系统性血管炎。未发现低AT III水平与血栓栓塞性疾病之间存在显著相关性。在30例证实存在狼疮抗凝物的患者中观察到功能性AT III活性有明显变化。讨论了这种关联的意义。